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Abstract: RNA interference (RNAi) is a potent and specific post-transcriptional gene silencing
process. Since its discovery, tremendous efforts have been made to translate RNAi technology into
therapeutic applications for the treatment of different human diseases including respiratory diseases,
by manipulating the expression of disease-associated gene(s). Similar to other nucleic acid-based
therapeutics, the major hurdle of RNAi therapy is delivery. Pulmonary delivery is a promising
approach of delivering RNAi therapeutics directly to the airways for treating local conditions and
minimizing systemic side effects. It is a non-invasive route of administration that is generally well
accepted by patients. However, pulmonary drug delivery is a challenge as the lungs pose a series of
anatomical, physiological and immunological barriers to drug delivery. Understanding these barriers
is essential for the development an effective RNA delivery system. In this review, the different
barriers to pulmonary drug delivery are introduced. The potential of RNAi molecules as new class of
therapeutics, and the latest preclinical and clinical studies of using RNAi therapeutics in different
respiratory conditions are discussed in details. We hope this review can provide some useful insights
for moving inhaled RNAi therapeutics from bench to bedside.
Keywords: RNA interference; short interfering RNA (siRNA); short hairpin RNA (shRNA);
microRNA (miRNA); pulmonary delivery; respiratory diseases; inhalation
1. Introduction
Lung diseases are among the leading causes of death worldwide. Current treatment of lung
diseases such as lung cancer [1], respiratory infections [2,3], inflammatory diseases [4,5] and pulmonary
fibrosis [6] have limited efficacy. Almost two decades ago, double-stranded RNAs (dsRNAs)
were discovered to play an important role in regulating gene functions by a sequence-specific
post-transcriptional gene silencing mechanism called RNA interference (RNAi) [7]. The therapeutic
potential of RNAi was soon realized. It presents a new and powerful approach to treat or prevent many
diseases including respiratory disorders by modulating gene expression [8–13]. RNAi can be mediated
by various types of RNA molecules, including long dsRNA, short interfering RNA (siRNA), short
hairpin RNA (shRNA) and microRNA (miRNA). The mechanism of RNAi is illustrated in Figure 1,
and the general properties of different types of RNAi molecules are summarized in Table 1.
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Table 1. Comparison of general properties between long double-stranded RNA (dsRNA), short
interfering RNA (siRNA), short hairpin RNA (shRNA) and microRNA (miRNA).
Properties Long dsRNA siRNA shRNA miRNA
Structure ds, 500–1000 ntduplex
ds, 21–23 nt in length
with 2 nt 3′ overhang
50–70 nt with a stem-loop
structure (pre-shRNA),
cleaved by Dicer to give
RNA duplex with
structure similar to siRNA
pre-miRNA: 70–100 nt with a
stem-loop structure containing
bulges/mismatches miRNA:
18–25 nt in length with
2 nt 3′ overhang
Synthesis
Exogenous; or
chemically
synthesized
Processed from long
dsRNA; expressed from
shRNA vector; or
chemically synthesized
Expressed from shRNA
vector
Endogenous; expressed from
miRNA vector; or chemically
synthesized
Risk of
immunogenicity High Moderate Low Low
Level of
complementary
Fully complementary
to mRNA
Fully complementary
to mRNA
Fully complementary
to mRNA
Partial complementary to
mRNA (3′UTR of mRNA)
mRNA target Single target Single target Single target Multiple targets
Notes: ds, double stranded; nt, nucleotide; UTR, untranslated region.
Molecules 2016, 21, 1249 2 of 31 
 
Table 1. Comparison of general properties between long double-stranded RNA (dsRNA), short 
interfering RNA (siRNA), short hairpin RNA (shRNA) and microRNA (miRNA). 
Properties Long dsRNA siRNA shRNA miRNA 
Structure 
ds, 500–1000 nt 
duplex 
ds, 21–23 nt in length 
with 2 nt 3′ overhang 
50–70 nt with a stem-loop 
structure (pre-shRNA), 
cleave  by Dicer to give 
RNA duplex with structure 
similar to siRNA 
pre-miRNA: 70–100 nt with a 
stem-loop structure containing 
bulges/mismatc es miRNA: 
18–25 nt in le th with  
2 nt 3′ overhang 
Synthesis 
Exogenous; or 
chemically 
synthesized 
Processed from long 
dsRNA; expressed 
from shRNA vector; or 
chemically synthesized 
Expressed from shRNA 
vector 
Endogenous; expressed from 
miRNA vector; or chemically 
synthesized 
Risk of 
immunogenicity 
High Moderate Low Low 
Level of 
complementary 
Fully complementary 
to mRNA 
Fully complementary 
to mRNA 
Fully complementary to 
mRNA 
Partial complementary to 
mRNA (3′UTR of mRNA) 
mRNA target Single target Single target Single target Multiple targets 
Notes: ds, double stranded; nt, nucleotide; UTR, untranslated region. 
Figure 1. Mechanism of RNA interference (RNAi) induced gene silencing. Short interfering RNA 
(siRNA) can be produced inside the cells from double stranded RNA (dsRNA) or expressed from short 
hairpin RNA (shRNA) vector, or chemically synthesized in the laboratory. Its gene silencing effect is 
dependent upon fully complementary binding of the target messenger RNA (mRNA). MicroRNA 
(miRNA) is a naturally occurring molecule. It can also be expressed from miRNA vector or chemically 
synthesized (miRNA mimic). miRNA mediates gene silencing via the partial complementary binding 
of the target mRNAs. 
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Figure 1. Mechanism of RNA interference (RNAi) induced gene silencing. Short interfering RNA
(siRNA) can be produced inside the cells from double stranded RNA (dsRNA) or expressed from short
hairpin RNA (shRNA) vector, or chemically synthesized in the laboratory. Its gene silencing effect
is dependent upon fully complementary binding of the target messenger RNA (mRNA). MicroRNA
(miRNA) is a naturally occurring molecule. It can also be expressed from miRNA vector or chemically
synthesized (miRNA mimic). miRNA mediates gene silencing via the partial complementary binding
of the target mRNAs.
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1.1. Long dsRNA and siRNA
Long dsRNAs (around 500–1000 nucleotides in length) have been employed to study gene
functions. After the exogenous dsRNA is introduced into the cytoplasm of the cells, it is cleaved by
RNase III enzyme Dicer into short dsRNA called siRNA. The siRNA which is 21–23 nucleotides in
length is loaded into a protein complex called the RNA-induced silencing complex (RISC). The siRNA
is then unwound, and the sense strand (also known as the passenger strand) of the siRNA is degraded,
whereas the remaining antisense strand (also known as the guide strand) guides the activated RICS to
the target messenger RNA (mRNA) through full complementary binding. The mRNA is then cleaved
by Argonaute 2 (Ago2) in the RISC, leading to the silencing of the target gene [14,15]. Since long
dsRNA is known to trigger immunostimulatory response through the activation of Dicer-related
antiviral pathways and induction of type 1 interferon (IFN) [16], it is less suitable for therapeutic use.
In contrast, synthetic siRNA is a more promising gene silencing mediator because of the lower risk of
immune response. It is also the most widely investigated RNAi molecule for therapeutic applications,
with over 26 clinical trial studies being initiated since 2004 [17].
1.2. shRNA
shRNA is a sequence of RNA transcribed in the nucleus of the cells from a DNA vector by either
RNA polymerase II or III. The primary transcript is called primary shRNA (pri-shRNA), which contains
a hairpin like stem-loop structure. The pri-shRNA is processed into a 50–70 nucleotides long loop-stem
precursor shRNA (pre-shRNA) by a protein complex containing the RNase III nuclease Drosha and the
dsRNA binding domain protein DGCR8. It is then transported to the cytoplasm through a specialized
nuclear membrane protein, exportin-5 (Exp5). The loop sequence of the pre-shRNA is cleaved by the
Dicer to form a double-stranded siRNA. This endogenously produced siRNA is loaded into RISC and
induce RNAi through the similar process as the synthetic siRNA [18,19]. Since shRNA expression unit
can be incorporated into viral vectors and continuously synthesized by the host cell, it can induce
long-lasting gene silencing effect. The RISC-loading process of shRNA is about ten times more efficient
than siRNA, implicating that lower dose of shRNA is required to maintain the therapeutic efficacy with
less off-target effect [20]. However, the shRNA approach is a DNA-based strategy depending on the
expression of shRNA encoding gene which often requires viral vectors. From the delivery perspective,
the introduction of synthetic siRNA to the cytoplasm is a more straightforward way to induce RNAi.
The use of viral vectors for delivery poses safety concerns in its therapeutic applications [15].
1.3. miRNA
miRNA is a naturally occurring non-coding RNA that plays a key role in regulating gene
expression. Primary miRNA (pri-miRNA) is transcribed by RNA polymerase II from endogenous
miRNA gene in the nucleus. The hairpin-containing pri-miRNA is structurally similar to the
pri-shRNA, therefore the maturation pathway of miRNA is also similar to shRNA [18]. The pri-mRNA
is converted by Drosha/DCGR8 complex into precursor miRNA (pre-miRNA), which contains
70–100 nucleotides with interspersed mismatches and adopts a loop structure. The pre-miRNA
is subsequently transported to the cytoplasm by Exp5, and is processed by the Dicer into mature
miRNA of 18–25 nucleotides in length [21]. As opposed to siRNA, the antisense strand of miRNA is
only partially complementary to the target mRNA, leading to gene silencing via translational repression
and/or mRNA deadenylation. Position 2 to 7 of the 5′ end of the miRNA is the “seed sequence”,
which is essential for target recognition, and the miRNA binding sites of mRNA are located in the
3′ untranslated region (UTR) [22]. There are two major approaches of miRNA-based therapeutics:
(i) miRNA inhibition [23,24], which suppresses the action of the endogenous miRNA by antisense
oligonucleotide (antimiR); and (ii) miRNA replacement [25,26], which introduces synthetic miRNA
(miRNA mimic) to restore the functions of the endogenous miRNA. Only the latter is discussed in this
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review. Compared to siRNA-based therapeutics, miRNA has the potential to target multiple genes
due to the imperfect binding to the target mRNA [27].
2. Pulmonary Delivery of RNAi Therapeutics
RNAi therapeutics offer several advantages over the traditional small molecules and protein-based
drugs. They could virtually target any genes with high selectivity, including those “undruggable”
targets. The design and synthesis of RNAi molecules are relatively simple because they do not need
a cellular expression system, complex protein purification, or refolding schemes [28]. Compared to
the antisense oligonucleotides, RNAi is more potent and specific [29]. Despite its huge therapeutic
potential, delivery remains to be a major barrier to the clinical application of RNAi therapeutics [30,31].
For the treatment of respiratory disorders, pulmonary route of administration can deliver RNAi
molecules directly to the site of action, thereby lowering the dose required while minimizing systemic
adverse effects. The RNAi molecules can also avoid the rapid clearance by serum nuclease in the
bloodstream. Moreover, inhalation is a non-invasive route of administration that is easily accepted by
patients compared to parenteral administration, leading to better patient compliance [14,32]. However,
pulmonary drug delivery is a challenge with several key biological barriers, which are highlighted in
Figure 2.
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2.1. Extracellular Barriers
u an respiratory tract is divided into the conducting region (nasal cavity, pharynx, trachea,
bronchi and bronchioles) and the respiratory region (respiratory bronchioles and alveoli). The former is
the pathway for gases conduction whereas the latter is the site of gaseous exchange [14]. The extensive
branched structure of the airways with varying length and diameter presents the primary hurdle in
pulmonary drug delivery. The mechanisms of inhaled particle deposition in the lungs include inertial
impaction, gravitational sedimentation, diffusion, interception and electrostatic precipitation [33].
As illustrated in Figure 3, the first three mechanisms are the major echanisms which are greatly
influenced by the aerodynamic size of the particles [34]. The optimal particle size for lung deposition
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is between 1 and 5 µm [35,36]. Larger particles are likely to be impacted and trapped on the upper
airway wall at bifurcations while the small particles from 0.1 to 1 µm are easily exhaled during normal
breathing. Smaller particles under 100 nm may be successfully deposited in the alveolar space because
of the increasing diffusional mobility [37]. However, aerosols under 100 nm are difficult to produce,
which make their application less favorable.Molecules 2016, 21, 1249 5 of 31 
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Figure 3. The three major mechanisms of particles deposition in the lungs. Inertia impaction occurs
when large particles (>5 µm) cannot adjust to the change of airflow direction due to inertia and deposit
on the airway walls, typically in the upper respiratory tract. Gravitational sedimentation is the settling
of particles due to gravitational force. It mainly affects particles with size of 1–5 µm, which usually
deposit in the small airways. Diffusion occurs when submicron-size particles having Brownian motion
hit the surface of airway walls.
The presence of fluid layers in the airways, including the mucus and the pulmonary surfactant,
also creates a barrier to the delivery of drug molecules to the lungs. Mucus is a gel of three-dimensional
ne work stru ture. It ac as a sieve that filters out large molecules (>500 nm) [38]. Mucins, wh ch re the
major componen s of mucus, contain the hydrophili glycosylated residues rich in serin and threonine
and the hydrophobic non-glycosylated cysteine-rich domains. This characte istic llow electrostatic,
hydrophilic a d hydrophobic interactions between mucus and drug particles [39]. Since mucus is
continuously produced, shed and replaced, and together with the mucociliary clearance action, the fast
turnover rate of ucus leads to the rapid clearance of the entrapped drug molecules, preventing them
from reaching the epithelium [40,41]. Moreover, cough clearance that occurs when the mucus reaches
the throat is another removal mechanism of RNAi molecules from the airways. On the other hand,
the role of pulmonary surfactant in nucleic acid delivery is controversial. Pulmonary surfactant is
composed of approximately 90% lipids and 10% proteins [42]. It has been suggested that the lipids
and proteins in the lung surfactant interact with the non-viral cationic lipid-based delivery system,
leading to the premature release of nucleic acids [43,44]. Conversely, polymer-based delivery systems
were found to be more compatible with pulmonary surfactant. Commercial pulmonary surfactant was
employed in the preparation of some polymeric nanoparticles to facilitate the cellular uptake of siRNA
to improve gene silencing effect [45,46].
Apart from the physical barriers, the RNAi molecules may undergo enzymatic degradation
following pulmonary delivery. RNA is extremely susceptible to nuclease activity. Naked siRNA has
a short half-life of less than 15 min in serum [47]. Due to the lack of serum in the lungs, t e half-life
of unmodifi d siRNA i the airways can reach up to thre hours in mouse [48]. RNAi molecules
may also be taken up and removed by alveolar macrophages upon lung deposition. Th alveolar
macrophages are responsible for engulfing and digesting for ign particles in the lower airways
via phagocytosis. Unless the targ t of RNAi molecules is locat d inside the macrophages, such as
Mycobacterium tuberculosis which is the causative agent of tuberculosis that typically reside in the
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alveolar macrophages [49], otherwise the RNAi molecules are subjected to degradation inside the
macrophages before reaching their target sites.
2.2. Intracellular Barriers
Once the RNAi molecules overcome the aforementioned extracellular barriers and reach the target
cells, they need to overcome a set of intracellular barriers. The ultimate site of actions depends on the
types of RNAi molecules. For synthetic siRNA and miRNA mimic, they need to reach the cytoplasm
where the RISC locates, whereas DNA encoding shRNA or miRNA need to enter the nucleus in order
for transcription to take place.
Surface adhesion is the first step of cellular entry. There are various endocytic mechanisms
involved in the cellular uptake of macromolecules, which subsequently influence their intracellular
trafficking and delivery efficiency [50–55]. The clathrin-dependent endocytosis is the most common
route of cellular entry for macromolecules [56]. Following cell entry, the RNAi molecules are entrapped
in the early endosomes where progressive acidification occurs. The late endosomes then fuse with the
lysosomes, which contain hydrolases that degrade the RNAi molecules [56,57]. The RNAi molecules
must escape from endosome at early stage to exert their biological effect. Strategies of endosomal
escape have been reviewed in other literatures [58–61]. For shRNA or miRNA vectors, nuclear entry
is an additional barrier which is particularly challenging due to the presence of nuclear membranes
that are impermeable to most substances except small non-polar molecules [62]. Non-viral vectors are
inefficient in delivering DNA into the nucleus. Some viruses are evolved to transport their genome
into the nucleus; hence, they become attractive DNA carriers to improve transduction efficiency.
However, poor safety profile, high production cost and the risk of immunogenicity [63] limited the
applications of viral vector mediated RNAi to laboratory tool.
3. Delivery Strategies of RNAi Molecules
A delivery vector or carrier is generally necessary to overcome the aforementioned barriers by
promoting cellular uptake and offering protection to the RNAi molecules. RNAi delivery system can
be categorized into viral and non-viral vectors according to their nature, and these delivery systems
have been extensively reviewed [63–67].
3.1. Viral Vectors
The viral vectors refer to the of use of viruses to deliver genetic materials to the cells. They are
extremely efficient in transducing cells and providing either transient or long-term gene expression,
depending on the type of viruses employed. Most of the in vivo studies used the adenoviruses,
adeno-associated virus (AAV) and retroviruses to express the plasmid DNA encoding shRNA or
miRNA to induce RNAi [68]. The most attractive property of viral vectors is that they have the ability
to access the nucleus of the cells. Thus, they have high efficacy to express the RNA and subsequently
regulate the gene expression [69–72]. However, the clinical application of viral vectors is limited by the
toxicity, insertional mutagenesis (associated with retroviruses) and immunogenicity (associated with
adenoviruses) [63]. In addition, the smaller size of AVV limits the amount of therapeutic gene that can
be inserted.
3.2. Non-Viral Vectors
Compared to viral vectors, non-viral vectors generally have better safety profile and lower
production cost. They have been investigated for the pulmonary delivery of the RNAi molecules.
Lipid-based, polymer-based and peptide-based are three major non-viral delivery systems [73].
The lipid-based vectors are the most commonly used vectors for RNAi delivery. They include cationic
liposomes, solid lipid nanoparticles, solid nanostructured lipid carriers, lipidoids and pH-responsive
lipids [74]. Many commercially available transfection agents (i.e., Lipofectamine, Oligofectamine,
TransIT-TKO and DharmaFECT) are lipid-based systems [75–78]. Despite the promising transfection
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efficacy, the major challenges of using the lipids are the immune response and cytotoxicity [79].
In addition to the lipids, biocompatible and biodegradable natural polymers such as chitosan and
dextran, as well as synthetic polymers such as poly lactic-co-glycolic acid (PLGA), polyethylenimine
(PEI) and PAMAM dendrimer are used for the preparation of polymeric nanoparticles for RNA
delivery [80–85]. The polymers have relatively low toxicity compared to the lipid-based vectors
and are more versatile for chemical modification. For peptide-based delivery systems, peptides
such poly(L-lysine) (PLL), cell penetrating peptides (CPPs) and pH-responsive peptides have been
investigated for the delivery of the RNAi molecules [86–90]. Different types of peptides mediate
cellular transfection via different mechanisms such as facilitating cellular uptake and promoting
endosomal escape. Peptides can be used to carry the RNAi molecules alone or act as a functional
component in other carriers. Currently, efficient peptides with low toxicity and high transfection
efficacy are still under development. It is noted that for pulmonary delivery, the reduced nuclease
activity in the lungs makes successful delivery of unmodified naked RNA become possible [91,92].
However, the mechanism of how naked siRNA could overcome the extracellular and intracellular
barrier following pulmonary administration still remains to be understood.
4. RNAi Therapeutics for the Treatment of Respiratory Diseases
The therapeutic potential of RNAi-based therapy targeting respiratory disorders has been widely
explored in the past decade. In the following sections, the pre-clinical and clinical studies that involved
the delivery of RNAi molecules to the airways for the treatment of lung diseases are discussed.
4.1. Lung Cancer
Lung cancer is a leading cause of cancer death in the world. The mainstay of treatment is
chemotherapy, which is indicated for around 70% of newly diagnosed patients with local and
advanced metastatic disease [93]. Other treatment options include surgery and radiotherapy [94].
Angiogenesis inhibitors [95] and epidermal growth factor receptor (EGFR) inhibitors [96,97] are new
medications licensed for the treatment of lung cancer. Despite various treatment options, the prognosis
of lung cancer is poor. The major problems of chemotherapy are toxicity, lack of specificity and drug
resistance [98]. In recent years, pulmonary delivery of RNAi molecules is being explored as a new
treatment for lung cancer [99]. Genes that are associated with tumor cell growth and drug resistance
are potential targets. Table 2 summarizes some recent in vivo studies of pulmonary RNAi delivery for
lung cancer treatment.
4.1.1. Inhibition of Tumor Cell Growth
Genes that are essential for tumor growth and progression, such as Akt1 (RAC-alpha
serine/threonine-protein kinase B) and c-myc, are evaluated as RNAi targets. Akt1 is an important
mediator of cell growth, proliferation and survival of non-small cell lung cancer (NSCLC). Activation of
Akt1 pathway is observed in most NSCLC patients. It is found to reduce chemo- and radiation-induced
apoptosis to extend the survival of tumor cells [100,101]. Sorbitol diacrylatepolyethylenimine
(SDA-PEI) was employed to deliver shRNA targeting Akt1 (shAkt1) and cDNA encoding programmed
cell death protein 4 (Pdcd4) in a dual expression vector via pulmonary route to murine lung cancer
model. Simultaneous Akt1 inhibition and Pdcd4 overexpression could induce potent anticancer effect.
The total tumor number and the tumor size larger than 1 mm in the lung were significantly reduced
after eight doses [101]. Glycerol triacrylate–spermine (GT–SPE) polyspermine [102] and lentivirus [103]
were also employed as carriers of shRNA targeting Akt1 signaling pathway for pulmonary delivery.
Although repeated aerosol delivery of lentiviral-based shRNA can achieve potent knockdown of the
target, inhalation is a procedure that generates large number of viral particles. There are safety concerns
regarding the use of viral vectors for inhalation, including the potential mutagenicity, immunogenicity
and the risk of aerosol-transmitted infections [104]. Therefore, aerosol delivery of RNAi molecules
using viral vectors must go through vigorous biosafety evaluation for clinical use.
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Table 2. Selected in vivo studies of inhaled RNAi therapy on the treatment of lung cancer in the past five years.
RNAi Administration/DeliverySystem Methods Key Observations Ref. Year
Akt1 shRNA Inhalation/SDA-PEI
400 µg of dual expression vector (shRNA and Pdcd4 cDNA)
was administered to mouse with lung cancer twice a week
for 4 weeks
Inhibition of Akt1 and overexpression of Pdcd4
synergistically suppressed lung tumorigenesis [101] 2015
Bcl-2 siRNA Intratracheal/PEI conjugatedwith DOX
20 µg siRNA and 10 µg DOX was administered to mouse on
day 3, 10 and 17 after B16F10 cell implantation
Co-administration of siRNA and DOX enhanced
antitumor effect compared with DOX or siRNA alone [105] 2015
EGFP siRNA Intratracheal/Chitosan(as dry powder)
30 µg siRNA (1.5 mg dry powder formulation) was
administered to mouse with lung tumors stably
expressing EGFP
EGFP expression in lung tumors consisting of EGFP cells
was effectively silenced [9] 2015
RPN2 PnkRNA Intratracheal/Naked PnkRNA 15 µg of PnkRNA was administered to lung cancer xenograftmouse model as single dose or once a week for 3 weeks
Lung tumor growth was significantly inhibited without
serious toxicity [106] 2013
c-myc siRNA Intratracheal/RGD gold NPs 0.3 or 1 pmol NPs were administered to mouse at week 12, 13,14 and 15 after lung cancer induction
Tumor cell proliferation and tumor size were successful
suppressed; the survival of animal was also prolonged [107] 2013
NPT2b siRNA Inhalation/GPT-SPE 500 µg of siRNA was administered to mouse with lungcancer twice a week for four weeks
Lung cancer growth, cancer cell proliferation and
angiogenesis was suppressed, apoptosis was facilitated [108] 2013
AIMP2-DX2 shRNA Inhalation/Lentivirus 2 µg of shRNA was administered to AIMP2+/−mouse(susceptible to tumorigenesis) twice a week for four weeks Expression of AIMPS-DX2 was suppressed [103] 2013
Luciferase siRNA Intratrachael/Chitosan(as dry powder)
30 µg siRNA (1.5 mg powder formulation) was administered
to mouse with lung metastasis (tumor cells stably expressing
luciferase gene) twice a day for two days
Significant inhibition of the increase in luminescence
intensity in the lungs [109] 2013
Bcl-2 and MRP1 siRNA Inhalation/Lipid-based NPs 170 µg/kg of siRNA (1:1 Bcl-2:MRP1) to mouse orthotopiclung cancer model
Enhanced antitumor activity and reduced adverse
effects (compared with intravenous treatment) [110] 2013
Akt1 shRNA Inhalation/GT–SPE 400 µg shRNA was administered to mouse with lung cancertwice a week for 4 weeks Lung tumorigenesis was suppressed [102] 2012
Notes: AIMP2-DX2, aminoacyl-tRNA synthetases (ARS)-interacting multifunctional protein 2 lacking exon 2; Akt1, RAC-alpha serine/threonine-protein kinase B; Bcl-2, B-cell
lymphoma 2; DOX: doxorubicin; EGFP, enhanced green fluorescence protein; GPT-SPE: glycerol propoxylate triacrylate and spermine; GT–SPE, glycerol triacrylate–spermine;
MRP1, multidrug resistance protein 1; NPT2b: sodium-dependent phosphate co-transporter 2b; Pdcd4: programmed cell death protein 4; PEI: polyethylenimine; RGD,
Arginine-glycine-aspartic acid peptide; RPN2, ribophorin II; NPs, nanoparticles; SDA-PEI, sorbitol diacrylatepolyethylenimine; TAX, paclitaxel.
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C-myc oncogene is a downstream conduit for most oncogenic signals. It is necessary for the
growth control, differentiation and apoptosis. Abnormal expression of c-myc is associated with many
tumors. De-activation of myc is efficacious for lung tumor therapy [111]. Conde et al. delivered siRNA
targeting c-myc to the lung of mouse using RGD-surface-modified gold nanoparticles (AuNPs) by
intratracheal instillation. RGD peptide (Arg-Gly-Asp) is a cell adhesion peptide responsible to mediate
cell adhesion and proliferation by binding to the integrin avb3 receptor family, a specific marker
for angiogenesis and up-regulated in the endothelium. This strategy successfully suppressed c-myc
expression level and tumor cell proliferation, resulting in approximately 80% increase in survival of
orthograft mouse tumor models [107].
4.1.2. Targeting Multidrug Resistance (MDR)
Genes associated with MDR were also evaluated as target of RNAi, such as ribophorin II
(RPN2) [106], B-cell lymphoma 2 (BCL-2) [112] and multidrug resistance protein 1 (MRP1) [110]. RPN2
is known to be associated with the apoptosis in docetaxel-resistant human breast cancer cells [113],
and its involvement in NSCLC was investigated recently [114]. A novel RNAi molecule (PnkRNA)
targeting RPN2 was developed and delivered to mice bearing lung cancer by intrapulmonary delivery.
This new class of RNAi agent has a unique helical structure containing a central stem and two loops,
and is claimed to be stable against nuclease degradation. Inhibition of lung tumor growth was observed
without any signs of toxicity after treatment. The antitumor effect was triggered by PnkRNA targeting
RPN2 without the use of other anticancer drugs. It could be attributed to the multiple activities
of RPN2, which is anti-apoptotic and involved in the regulation of tumor survival [106]. However,
the mechanism of how the naked the PnkRNA molecules overcame the extracellular and intracellular
barriers to initiate RNAi was not elucidated.
Besides the inhibition of MDR associated proteins alone, the co-delivery of anticancer drugs with
RNAi therapeutics is as an alternative approach to tackle MDR in various types of cancers [112,115–117].
Combination therapy offers the potential advantages of synergistic activity, overcoming the drug
resistance and reducing the side effects of chemotherapy. Bcl-2 is a main player of nonpump cellular
resistance [118] and MRP1 is responsible for drug efflux in cancer cells [119]. They were investigated
in the combination approach. Taratula et al. prepared a lipid-based nanoparticles containing siRNA
targeting Bcl-2 and MRP1, as well as anticancer drugs (doxorubicin or paclitaxel). The nanoparticles
were delivered to the lung of tumor mouse model using a nose only exposure chamber for inhalation.
Almost complete disappearance of lung tumor was observed in animals treated with paclitaxel plus the
siRNAs. In contrast, treatment with paclitaxel alone only slowed down the growth of the tumor [110].
Xu et al. developed a polyethylenimine (PEI)-based delivery system that simultaneously delivered
siRNA targeting Bcl-2 and doxorubicin to the lungs of mice with metastatic lung cancer. Synergistic
antitumor efficacy was achieved compared with the delivery of doxorubicin or siRNA alone [105].
These studies indicated that suppression of resistance gene by RNAi molecules via inhalation could
restore the sensitivity of chemotherapeutic drugs, leading to the death of tumor cells.
4.2. Respiratory Infection
Respiratory infection can be caused by a wide range of microorganisms in the airways including
bacteria and viruses [120]. It is one of the most common reasons for hospitalization among adults [121].
Due to the rise of antimicrobial resistance, many infectious diseases including respiratory infections
have become difficult to treat. RNAi therapeutics appears to be an attractive approach to fight against
infections [122]. The pre-clinical studies of RNAi therapeutics to combat against respiratory infections
are summarized in Table 3.
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Table 3. Selected in vivo studies of using RNAi therapy on respiratory infections.
RNAi Administration/DeliverySystem Methods Key Observations Ref. Year
RSV
P protein siRNA Intranasal/Naked siRNA orTransIT-TKO
5 nmol (~70 µg) of siRNA was administered to mouse at
time of RSV and/or PIV infection
Animals were successfully protected from RSV and PIV
infections specifically [123] 2005
N protein siRNA Intranasal/Naked siRNA 100 µg of siRNA was administered to mouse beforeinfection (single dose) or after infection (multiple doses)
Significant reductions of viral load was achieved in both
prophylactic and therapeutic regimens [124] 2009
Influenza A
NP, PB1 shRNA Intranasal/Infasurf 60 µg of shRNA (expressing NP, PB, or NP + PB1) wasadministered to mouse 13 h before infection
Decreased lung viral titers in animals treated with
shRNA expressing NP; the reduction was more
significant with shRNA expressing both NP and PB1
[125] 2004
NP and PA siRNA Intranasal andhydrodynamic/Oligofectamine
1.5 nmol (~20 µg) of siRNA was administered by
hydrodynamic injection to mouse 16–24 h before
infection, second dose was administered at the same
time of infection by intranasal instillation
Treated animals were protected from lethal challenge
with highly pathogenic viruses [126] 2004
NP siRNA Intravenous/PEI 120 µg of siRNA was administered to mouse 3 hprior to infection A 94% drop of virus titers in the lungs of infected mice [127] 2005
M2 and NP siRNA
expression plasmids Intravenous/PEI
100 µg of DNA was administered to mouse 15 h
prior to infection
Significant reduction of lung virus titers; treated animals
were partially protected from lethal virus challenge [128] 2007
NP, PA and PB1 siRNA
expression plasmids Intravenous/adenovirus
100 µg of DNA was administered to mouse 18 h
prior to infection Virus production in mice was potently inhibited [129] 2008
Tuberculosis
XCL1 siRNA Intratracheal/Naked siRNA 5, 10 or 15 µg of siRNA was administered to Mtbinfected mouse
XCL1 expression in the lungs was significantly
suppressed; decreased T lymphocytes,
IFN-γ response and disorganized granulomatous
lesions and high fibrosis
[130] 2009
TGF-β1 siRNA Intratracheal/Naked siRNA
Three doses at 5 days intervals of 10 µg of siRNA per
dose were administered to IL-10 knockout mouse
starting on day 60 post-infection
Expression of antimicrobial mediators (NO and iNOS)
was effectively increased along with the reduction of the
bacterial load in the lungs of treated mice
[13] 2011
Notes: iNOS: nitric oxide synthase; Mtb: Mycobacterium tuberculosis; M2: influenza virus matrix protein; NO, nitric oxide; NP, nucleocapsid protein; P protein: phosphoprotein;
PA: polymerase acidic protein; PB, polymerase basic protein; PEI, polyethyleneimine; PIV, parainfluenza virus; RSV, respiratory syncytial virus; TGF: transforming growth factor;
XCL1, lymphotactin.
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Since RNAi was first reported to inhibit respiratory syncytial virus (RSV) in 2001 [131],
an increasing number of studies have been initiated to explore the potential of RNAi technology to
treat other respiratory viral infections including influenza [86,127,132,133] and severe acute respiratory
syndrome (SARS) [134]. RNAi molecules offer several advantages as antiviral therapeutics. They can
specifically target the conserved region of mRNA sequence in the viral genome, making it effective
against mutated viral strains. In addition, RNAi molecules can be designed rapidly to target viral
genes, shortening the lead time of developing new antiviral agents, which is particularly useful
in response to an infection outbreak. To achieve effective antiviral effect, the viral targets must be
essential for the pathogenesis of viral infection and/or replication cycle. It is also desirable that the
target genes share similar conserved sequence among different strains to achieve broad viral inhibition.
Furthermore, the viral gene should be substantially different with human gene to minimize any
undesirable side effects.
4.2.1. RSV Infection
RSV infection is one of the most common infections in children [2,135]. In adult, RSV infection
usually leads to self-limited upper respiratory illness [136]. However, severe RSV infection has
been observed in elderly patients with lung diseases or in immunocompromised patients [137].
Current management of RSV includes bronchodilators, corticosteroids, antibiotics and supportive
care [2], but their efficacy is not satisfactory. To date, there is no licensed vaccine available to prevent
this disease [138]. There is an unmet need to develop effective RSV therapeutics and vaccines in both
the pediatric and adult population.
In 2005, Bitko et al. reported the inhibition of RSV and parainfluenza virus (PIV) replication
by siRNA targeting viral phosphoprotein (P protein), a crucial subunit of the viral RNA-dependent
RNA polymerase. Since RSV replicate primarily in the superficial layer of the respiratory epithelium,
local delivery of RNAi molecules to the lungs is a rational approach to inhibit RSV replication [139].
In the study, TransIT-TKO was employed as transfection agent and the siRNA was administered to
the lungs of BALB/c mice by intranasal instillation 4 h before viral challenge. The RSV and PIV titer
was reduced by over 90% five days after infection. The use of naked siRNA also showed substantial
inhibition of infection, with approximately 70%–80% efficiency achieved as compared to complexed
siRNA. Interestingly, the administration of siRNA before and concomitant with RSV infection was
more effective in reducing viral load than treatment after infection [123]. The prophylactic regimen
may not be a clinically attractive approach. To achieve optimal therapeutic benefit, fast detection and
early intervention are crucial for the prognosis of RSV infection. It is desirable to initiate the antiviral
RNAi therapy as quickly as possible once RSV infection is confirmed in clinical practice.
P protein may not be an ideal target as it is limited by its specificity to a particular viral
strain [124]. Another siRNA, ALN-RSV01, was designed to target the highly conserved region of
the mRNA encoding viral nucleocapsid protein (N protein). N protein is a core protein in the RNA
polymerase and plays a key role in the replication cycle of RSV [140]. After intranasal administration
of ALN-RSV01 to the lungs of mouse at 4 h prior to viral infection, 2.5- to 3.0-log-unit reductions in
viral load was observed in comparison with the mismatch siRNA control. For the treatment regimen,
comparable antiviral efficacy was achieved in multiple daily doses of ALN-RSV01 at day 1, 2 and
3 post-infection [124].
The phase I clinical study of ALN-RSV01 was reported in 2008 [139]. Intranasal administration
of ALN-RSV01 was well tolerated and the side effect profile was similar to placebo. Later in 2010,
the antiviral effect of ALN-RSV01 was evaluated in a phase II trial. ALN-RSV01 was administered
by nasal spray daily to healthy adults for two days before and for three days after RSV inoculation.
The group treated with ALN-RSV01 had a significantly lower number of RSV infection compared to the
placebo group [140]. Another phase II b clinical trial of ALN-RSV01 in RSV-infected lung transplant
patients was also completed [141]. The primary endpoint of the study was to evaluate the effect
of ALN-RSV01 on the incidence of new or progressive bronchiolitis obliterans syndrome (BOS) in
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RSV-infected lung transplant patients. Even though the study marginally missed the primary endpoint
statistically (p = 0.058), inhaled ALN-RSV01 treatment induced a clinically meaningful reduction in
the incidence of BOS, reinforcing the potential of inhaled RNAi as new antiviral therapeutics.
4.2.2. Influenza
Seasonal influenza viruses, especially influenza type A virus, cause annual epidemics that led to
millions of death worldwide [142]. It is one of the major public health problems. Two categories of
antiviral drugs are currently approved to treat influenza, including M2 ion-channel protein inhibitors
(adamantanes) and neuraminidase inhibitors (zanamivir and oseltamivir). However, some influenza
A virus strains have shown to be resistant to these drugs [143,144], making the development of
new antiviral drug urgently needed. A number of studies were carried out to investigate the use of
RNAi to inhibit viral gene expression and protect cells from influenza infection. The most commonly
investigated targets are the nucleocapsid protein (NP), polymerase acidic protein (PA) and polymerase
basic protein (PB). These proteins are indispensable to influenza viral replication. More importantly,
they are highly conserved across different subtypes of influenza virus strains [132].
The first animal study applying RNAi against influenza was reported by Ge et al. [145]. siRNA
targeting NP or PA were complexed with PEI. The complexes were injected intravenously to the mice
3 h before or 5 h after influenza virus (PR8 H1N1) infection. The antiviral effect of siRNA targeting
NP was dose-dependent and combination of siRNAs targeting NP and PA enhanced the effect. In the
same study, shRNA targeting NP or PB was also investigated. The DNA was mixed with Infasurf,
a commercial available pulmonary surfactant. After intranasal instillation, a significant reduction of
virus titer was detected 24 h after infection although the effect was less prominent compared with
intravenous injection of PEI complexes. Infasurf may play a role as nucleic acid carrier. Little is known
about the interaction between DNA and pulmonary surfactant in the airspace. It could be possible that
the DNA interacted with the charged lipid components in the pulmonary surfactant leading to the
efficient spread and absorption in the airways [146].
Another study reported the administration of siRNA targeting NP and/or PA in lipid carrier
to influenza-infected mice by hydrodynamic injection and intranasal administration. The combined
siRNA delivery method effectively protected animals against lethal challenge of highly pathogenic
avian influenza A viruses, including the H5N1, H7N7 and H9N2 subtypes [126]. Since then,
the potential of siRNA for the treatment of influenza virus infection was continuously evaluated
in vitro [133,147–149] and in vivo [127–129]. However, the exploration of RNAi for the treatment
of influenza appears to reach the bottleneck. It could be partly attributed to the criticism of the
antiviral effect induced by siRNA, which was due to innate immune response rather than viral
inhibition through RNAi. Development of chemically modified RNAi molecules with minimal
immunostimulatory effect could be helpful to delineate the mechanism of the antiviral effects [150].
4.2.3. Tuberculosis
Tuberculosis (TB) is a bacterial lung infection caused by Mycobacterium tuberculosis (Mtb). Because
of the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB, the slow
development of new anti-TB agents and the inefficiency of vaccination, TB is still a major global health
problem. WHO reported that 9.6 million people suffered from TB in 2014 and 1.5 million die annually
because of the disease [151]. A new and effective TB therapeutics is highly sought after.
The approach of RNAi-based therapeutics against TB aims to modulate the gene expression of the
host instead of the bacillus because bacteria do not contain the requisite machinery for RNAi. Currently,
RNAi has been investigated for TB treatment in two directions: (i) targeting the host factors that are
essential for the survival of mycobacteria; and (ii) modulating the host immune response to facilitate
the elimination of mycobacterium [49]. Autophagy is a host defense mechanism against Mtb. Boosting
autophagy could be an effective strategy to promote the eradication of the mycobacteria. Hence,
a number of host factors that are involved in the regulation of autophagy were explored as the target
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of RNAi, including Bfl-1/A1 [152], Rap22a [153], Ras homologue enriched in brain (Rheb) [154] and
UV radiation resistance-associated gene (UVRAG) [155]. Down-regulation of these factors promoted
autophagosome formation and reduced the bacterial growth. However, the existing studies of using
RNAi to suppress host factors are preliminary and in vivo data is lacking. Moreover, it was recently
reported that autophagy pathway may not be essential for restricting Mtb growth [156]. Further
investigations are required to understand the relationship between Mtb infection and autophagy
pathway, and to better position the approach of RNAi for the control of tuberculosis infection.
Another strategy is to modulate host immune response to improve the antimicrobial ability
of the host [49]. One of the key characteristics of TB infection is the formation of granuloma,
which is a compact, organized aggregate of immune cells. Granuloma is previously considered
as a host-protective structure to sequester the infecting mycobacteria, but recent work revealed
that the pathogens could take advantage of granuloma formation to facilitate their proliferation
and dissemination in the host [157], as it provides a hospitable environment for mycobacteria to
survive and replicate over a long period of time. There is a complicated chemokines and cytokines
network involved in the granulomatous response. RNAi can be used to target immunosuppressive
cytokines in order to inhibit the growth of Mtb. Among them, tumor necrosis factor (TNF)-α and
IFN-γ are critical in activating macrophages and triggering the formation of granuloma [158]. XCL1
(lymphotactin) is a chemokine produced by activated CD8+ T cells during chronic TB infection. It was
suggested that XCL1 regulates IFN-γ production by CD4+ T cells and contribute to the stability of the
granuloma [159]. When a single dose of siRNA targeting XCL1 was delivered to the lungs of mice that
were chronically infected with TB, the expression of XCL1 was effectively inhibited. The suppression of
XCL1 expression in the lungs was associated with the decreasing number of T lymphocytes, reduction
in the IFN-γ response, disorganized granulomatous lesions and higher fibrosis [130]. Although the
inhibition effect elicited by siRNA was transient and did not provide significant therapeutic benefit,
this proof-of-concept study demonstrated that the local-environment and immunopathology of the
lungs can be modulated to favor host response via pulmonary delivery of siRNA.
Other targets of RNAi-based immunotherapy include the transforming growth factor β (TGF-β)
and interleukin 10 (IL-10) [13]. Both of them are found to be elevated in TB patients, and their high level
of expression is connected with TB reactivation [160]. During chronic infection, these cytokines restrain
inflammation through affecting helper T cell 1 (Th1) response and macrophage activation, leading
to substantial reduction of their antimicrobial activity [161]. In that study, siRNA targeting TGF-β1
was administered through the intrapulmonary route to IL-10 knockout mice at 60 days post-infection.
TGF-β1 gene silencing resulted in the increased expression of the antimicrobial mediators nitric oxide
(NO) and inducible nitric oxide synthase (iNOS), and significantly reduced the bacterial load for at
least four weeks after treatment. A synergistic effect at improving the antimicrobial activity in the lungs
was observed when both IL-10 and TGF-β1 were targeted simultaneously. Although the inhibition of
bacterial load in this study was modest, it showed that siRNA immunotherapy is a feasible approach
to enhance the host antimicrobial capacity. Moreover, MDR and XDR TB pose huge challenges for
the current chemotherapeutic agents. Combined immunotherapy targeting immunosuppressive
cytokines and chemotherapy to target drug resistance bacteria population is a direction that is worth
future investigation.
4.3. Respiratory Inflammatory Disease
Respiratory inflammatory diseases impose substantial healthcare burden worldwide as many of
the patients are inadequately controlled by current therapies [4,5,162]. These diseases are characterized
by inflammation in the respiratory tract, which is manifested with increased expression of inflammatory
cytokines and chemokines [163,164]. The common lung inflammatory diseases include asthma, chronic
obstructive pulmonary disease (COPD) and acute lung injury (ALI). Table 4 lists the major in vivo
studies that examine the effects of RNAi molecules in respiratory inflammatory disease.
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Table 4. Selected in vivo studies of using RNAi therapy on respiratory inflammatory diseases.
RNAi Administration/DeliverySystem Methods Key Observations Ref. Year
Asthma
SOCS siRNA Intranasal/Naked siRNA 2 µM siRNA (~0.4 µg) was administered to OVA sensitizedand challenged mouse (total 10 doses, every 3 days)
Decrease in lung eosinophilia, significant reduction of AHR,
mucus secretion and collagen deposition in the airways [12] 2014
IL-4 siRNA and P protein
(anti-RSV) siRNA Intranasal/Naked siRNA
100 µg of IL-4 siRNA (3 doses) and 70 µg of anti-RSV siRNA
(single dose) were administered to OVA sensitized mouse
with RSV-induced exacerbation
Eosinophilia in BALF, AHR and airway inflammation were
significantly reduced [165] 2014
STAT6 siRNA Intratracheal andintranasal/Naked siRNA
2 mg/kg of siRNA was administered to OVA sensitized and
challenged rat for 3 consecutive days
Allergen-induced lung inflammation was
significantly reduced [10] 2014
STAT6 siRNA Intranasal/Naked siRNA 100 µg of siRNA (3 doses) was administered to OVAsensitized and challenged mouse
Expression of key cytokines (IL-4, IL-13) and
allergen-induced inflammation in lung tissues were
significantly reduced
[166] 2009
miR-1 mimic; mpl siRNA Intranasal/Naked siRNA 50 µg of miRNA mimic or mpl siRNA was administered toOVA sensitized and challenged mouse
miR-1 mimic blocked the inflammatory responses and IL-13
expression; mpl knockdown reduced lung inflammation, Th2
cytokine secretion and mucus secretion
[167] 2013
Rip2 siRNA Intratracheal/Naked siRNA 1 or 5 nmol of siRNA (~13 µg or 67 µg) was administered toOVA sensitized and challenged mouse for 3 consecutive days
OVA-induced cytokine release, inflammatory cell infiltration
and mucus hypersecretion were inhibited [168] 2013
Let-7 miRNA mimic Intranasal/Naked miRNA 50–300 nM microRNA was administered to OVA sensitizedand challenged mouse for 3 consecutive days
Expression of IL-13 was inhibited in the lungs ; suppression
of airway inflammation and AHR [169] 2011
GATA3 shRNA Intratracheal/Lentivirus 2.2 × 10
6 IFU of viral vectors were administered to OVA
sensitized and challenged mouse
Expression of Th2 cytokines, antigen-induced airway
inflammation and AHR were significantly inhibited [170] 2008
CD86 siRNA Intratrachael/Naked siRNA 12.5 µg of siRNA was administered to OVA sensitized andchallenged mouse
OVA-induced airway eosinophilia, AHR and cytokines
production was reduced [171] 2014
Syk siRNA Intranasal/Naked siRNA 10 µg of siRNA was administered to mouse for3 consecutive days
The recruitment of inflammatory cells in the BALF of allergen
sensitized mice was effectively inhibited [172] 2013
c-kit siRNA Intranasal/Naked siRNA 35 µg of siRNA was administered to OVA sensitized andchallenged mouse for 3 consecutive days
Airway mucus secretion and eosinophil infiltration in BALF
was effectively reduced [173] 2014
Fluorescently labeled siRNA Intratrachael/Tf-PEI 750 pmol of siRNA (~10 µg) was administered to OVAsensitized and challenged mouse for 4 consecutive days
Tf-PEI polyplexes selectively delivered siRNA to activated
T cells [174] 2016
Acute Lung Injury
S1PLyase siRNA Intratracheal/siRNA/HMGB1A/R3V6 ternary complex
300 pmol of siRNA (~4 µg) was administered to mouse
model of ALI induced by LPS
Expression of IL-6 and TNF-α in BALF and lung tissues and
the inflammatory response was significantly reduced [11] 2014
TNF-α siRNA siRNA Intratracheal/Naked siRNA;Intravenous/liposmes 50 µg TNF-α siRNA was administered to ALI mouse model
Systemic injection but not intratracheal delivery of TNF-α
siRNA significantly reduced incidence of ALI [175] 2012
Notes: AHR, airway hyperresponsiveness; ALI, Acute lung injury; BALF, bronchoalveolar lavage fluid; CD86, cluster of differentiation 86; C-kit, a stem cell factor receptor; DCs,
dendritic cells; HMGB1A, high mobility group box-1 A peptide; IFU, infectious unit; LPS, lipopolysaccharide; Mpl, myeloproliferative leukemia virus oncogene; OVA, ovalbumin;
R3V6, an arginine-rich peptide; Rip2, receptor-interacting protein 2; RSV, respiratory syncytial virus; S1Plyase, sphingosine-1-phosphate lyase, SOCS, Suppressors of cytokine signaling
protein 3; STAT6, signal transducer and activator of transcription factor 6; Syk, spleen tyrosine kinase; Tf-PEI, transferrin polyethylenimine; Th2, T helper 2 cells; TNF-α, tumor necrosis
factor-α; VEGFR, Vascular endothelial growth factor.
Molecules 2016, 21, 1249 15 of 32
4.3.1. Asthma
Asthma is characterized by the variable and reversible airflow obstruction, airway
hyperresponsiveness (AHR), mucus hypersecretion and chronic inflammation [176]. The most common
form of asthma is allergic asthma, which is triggered by environmental stimuli such as house dust
and seasonal pollen [177]. According to WHO, it is estimated that around 334 million peoples
have asthma worldwide [178]. The mainstay treatments of asthma are corticosteroids, β2-adrenergic
receptor agonists and leukotriene receptor antagonists, either alone or in combination. Although
these medications can manage the conditions in most of the patients, there are still challenges of
poor patient compliance, intolerability and long term adverse effects [179]. For persistent allergic
asthmatic patients, omalizumab which is an anti-immunoglobulin E (IgE) monoclonal antibody can
be used, but the high cost and parenteral administration make it less favorable [180]. Alternative
anti-inflammatory drugs are needed. Many inflammatory mediators are identified to be involved
in the pathogenesis of asthma and they are investigated as potential targets of RNAi therapy. These
include cytokines/chemokines [181], transcription factors [168], tyrosine kinases/tyrosine kinase
receptors [172] and co-stimulatory molecules [182].
In allergic asthma, there is predominant activation of CD4+ T helper 2 (Th2) cell-driven
inflammatory response [183]. T cell activation and Th2 cytokine expression are increased in the airways
of atopic asthma patients after exposure to allergen [184]. Th2-type cytokines, interleukin-4 (IL-4),
IL-5 and IL-13, are the main players in the pathology of allergic airway inflammation, contributing to
allergic sensitization, IgE production, eosinophil infiltration and AHR respectively [183,184]. Clinical
studies that examine the therapeutic potential of using monoclonal antibodies (mAbs) to neutralize
the bioactivity of IL-4 [185], IL-13 [186,187] and IL-5 [188] or target their receptors are in progress.
Similarly, RNAi technology can be employed to target these cytokines [169,181].
Targeting suppressor of cytokine signaling (SOCS) 3 is an alternative approach [12]. SOCS proteins
are negative regulators of cytokine signaling pathway, which are involved in Th2 cells mediated allergic
response via controlling the balance between Th2 and Th1 cells [189]. The expression of SOCS3 is a
pathological marker of allergic disease. After siRNA targeting, SOCS3 was intranasally administered
to the lungs of chronic asthmatic mouse model [12], the silencing of SOCS3 down-regulated the
expression of Th2 cell associated cytokines, IL-4, IL-5 and IL-13, leading to substantial reduction of
airway inflammation, AHR as well as IgE production. Reduction of mucus secretion and collagen
deposition was also detected in the airways. Besides Th2 cell, other T cells subsets, such as Th9 and
Th17 cells, also contribute the inflammatory response in asthma by releasing IL-9 and IL-17A. These
molecules may also be the potential targets for RNAi therapy [183]. Furthermore, the combination
of inflammatory and antiviral siRNAs is a prospective therapy for patients with virus-induced
exacerbation of severe uncontrolled asthma, in view of the report that respiratory viral infection
is related to 80% of asthma exacerbation in children and adults [190]. The therapeutic potential of
targeting IL-4 and P protein of RSV simultaneously by siRNAs was examined in a mouse model
of RSV-induced asthma exacerbation [181]. The intranasal delivery of the two siRNAs was able to:
(i) significantly suppress IL-4 mRNA expression and RSV replication in the lungs; (ii) reduce eosinophil
and neutrophil infiltration in bronchoalveolar lavage fluid (BALF); (iii) inhibit AHR and inflammation;
and (iv) increase interferon (IFN)-γ expression.
Many transcription factors including nuclear factor-κB (NF-κB) [168], signal transducer and
activator of transcription factor 6 (STAT6) [166] and GATA-binding protein 3 (GATA3) [170] are
involved in the production Th2 cytokine in the airways of patients with asthma. They were
investigated as targets for RNAi in the management of asthmatic inflammation. NF-κB plays a
key role in the expression of many pro-inflammatory proteins [191]. Inhibition of NF-κB pathway
in the lungs was reported to be beneficial in asthma model [176,192]. One approach to inhibit the
activation of NF-κB signaling pathway is to target receptor-interacting protein 2 (Rip2), which is a
transcriptional product and an activator of NF-κB. Suppression of Rip2 expression was achieved in
mice by intratracheal delivery of siRNA, resulting in the inhibition of ovalbumin (OVA)-induced
Molecules 2016, 21, 1249 16 of 32
cytokine release, inflammatory cell infiltration, mucus hypersecretion and serum IgE level. This result
suggested that Rip2 could be a novel therapeutic target for the treatment of asthma [168]. Consistent
with this finding, suppression of STAT6 [10] and GATA3 [170,193] in murine model of allergen-induced
asthma by RNAi significantly inhibited the expression of downstream Th2 cytokines. These studies
support the hypothesis of using RNAi molecules targeting transcription factors to manage airway
inflammation and AHR of asthma.
Tyrosine kinases, which are broadly classified into receptor and non-receptor types, play an
important role in activating the transcription factors for inflammatory gene expression upon activation
by the inflammatory signals [194,195]. The key receptor tyrosine kinases involved in the inflammatory
response in asthma include epidermal growth factor receptor (EGFR), c-kit (a stem cell factor receptor)
and vascular endothelial growth factor receptor (VEGFR), while the non-receptor forms are spleen
tyrosine kinase (Syk), Src and janus kinase (JAK) [196]. Syk is a pivotal intracellular signaling molecule
involved in the activation of several pro-inflammatory transcription factors [197]. Inhibition of Syk
expression by antisense oligonucleotides has proven effective in suppression of tracheal contraction
and pulmonary inflammation in animal models of OVA-induced asthma [198]. When naked siRNA
targeting Syk was administered to the lungs of allergen-induced asthma mice model via nasal
instillation, the recruitment of inflammatory cells in the BALF was reduced [194]. Similarly, intranasal
administration of siRNA targeting c-kit also induced a promising result in reducing mucus secretion
and airway inflammation in experimental asthma mouse model [173]. Moreover, clinical studies have
been performed on a siRNA targeting Syk (Excellair™ developed by ZaBeCor Pharmaceuticals, USA)
for the treatment of asthma. In the Phase I study, 75% of asthma patients receiving Excellair™ by
inhalation for 21 consecutive days showed improvement in breathing or reduced the usage of rescue
inhaler compared to placebo. The drug was well tolerated by patients without eliciting serious side
effects. A Phase II clinical trial Excellair™ has been initiated in 2009; the results are not yet available
during the preparation of this review [199,200].
Targeting dendritic cells (DCs) in the airways by RNAi is another strategy for the treatment
of asthma. DCs are antigen presenting cells that could be found in the airways [5,201]. They are
actively involved in the differentiation of Th2 cells and hence contribute to the progress of airway
inflammation [202]. DCs express co-stimulatory molecules, cluster of differentiation (CD) 80 and
86, on the surface. The binding of CD80/CD86 with CD28 and cytotoxic T lymphocyte-associated
antigen-4 (CTLA-4) molecules on T cells is necessary for priming naive T cells into Th2 cells [203].
Blocking CD80 and/or CD86 activity with pharmacological inhibitors can inhibit T cell activation and
alleviate AHR and pulmonary inflammation in mice exposed to aerosolized allergen challenge [204].
Likewise, intratracheal administration of siRNA targeting CD86 significantly reduced its expression in
the airway mucosa of mouse model of allergic asthma. CD86 siRNA treatment also contributed to the
amelioration of OVA-induced airway eosinophilia, hyperresponsiveness, the elevations of IgE in the
sera and the production of inflammatory cytokines in BALF [171].
4.3.2. COPD
COPD is a persistent lung disease characterized by irreversible chronic airflow limitation.
The disease is usually progressive and associated with an increased chronic inflammatory response
in the lungs [205,206]. It is the result of long term exposure to air pollutants and usually associated
with cigarette smoking [205]. It affects around 10% of the population in the world. It is the fourth
leading cause of death in most of the industrialized countries and expected to become the third
by 2020 [207]. Three classes of medications used to manage COPD are bronchodilators (including
β2-adrenergic receptor and anticholinergic drugs), corticosteroids and phosphodiesterase-4 inhibitor.
They are effective in relieving the symptoms of COPD, but none of them can reverse the progressive
deterioration in lung function or cure the disease [4,205]. It is desirable to develop a novel therapy that
can simultaneously control the symptoms and improve the long-term prognosis of the disease.
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Despite similar clinical features, the mechanisms of underlying airway inflammation in asthma
and COPD are different with distinct patterns of inflammatory cells and mediators being involved [163].
The mechanisms and the mediators that drive the progression of chronic inflammation and emphysema
in COPD are far from fully understood [208]. The major signaling factors involved in the pathogenesis
of COPD include TNF-α, CCL2, CXCL8, TGF-β and VEGF [206]. Many of the cytokines and
chemokines secreted in the airways of COPD patients are modulated by the NF-κB pathway [163].
Therefore, RNAi targeting NF-κB pathway can be a strategy for the management of COPD [176,209].
Current research work on RNAi therapy for COPD remains mainly in the in vitro stage, likely due
to the insufficient understanding of the highly complex mechanisms underlying the pathology of the
disease [120]. Moreover, the degree of airway inflammatory response is determined both by genetic and
epigenetic factors. Since multiple inflammatory mediators are involved in the disease process, blocking
a single type of molecule is unlikely to exert significant clinical impact [206]. miRNA has the advantage
of targeting multiple genes simultaneously. It is involved in the regulation of the inflammatory process
of COPD by modulating the transcription and translation of genes. Differentiated expression of several
miRNAs, like let-7c, miR-125b, miR-15b [210] and miR-199a-5p [211] were identified in COPD patients
compared to subjects without COPD. Modulation the expression of multiple genes using miRNA
could be a direction of RNAi therapy for the treatment of COPD.
4.3.3. Acute Lung Injury (ALI)
ALI is a severe form of diffuse lung disease that is commonly caused by acute systemic
inflammatory disorders, such as sepsis, pneumonia, trauma and pancreatitis [11,212]. It is a progressive
disease, which can lead to acute respiratory distress syndrome (ARDS) or more critically, multiple
organ failure and even death [175]. Its pathological changes include the release of pro-inflammatory
cytokines and chemokines, and the destruction of the epithelium-capillary interface; the latter can
facilitate the extravasation of protein-rich fluid and the infiltration of neutrophils, thereby exacerbating
the condition [213,214]. Since the molecular mechanism underlying the pathology of ALI is not well
understood, there is no pathophysiologic-driven therapeutic approach available [162].
RNAi targeting the essential inflammatory mediators could offer protection against the
progression of the disease. In an in vivo study, systemic delivery of siRNA targeting TNF-α
significantly reduced the expression of TNF-α in the lungs and lung injury in a shock-induced ALI
mouse model [175]. The findings suggested that pulmonary vascular cells, but not the epithelial cells,
contribute to the release of TNF-α leading to lung injury following a systemic inflammatory insult.
Although these findings are contradictory to the others who suggest that pulmonary epithelial cells
are the major players for causing lung injury induced by a systemic disease [215,216], nevertheless,
they provide evidence that support the use of siRNA targeting TNF-α in the management of ALI.
Increase microvascular permeability is a major cause of amplification of the inflammatory
responses in ALI, leading to the progression to severe pathological condition [214]. The integrity
of pulmonary and systemic endothelial barrier is maintained by the bioactive lipid, sphingosine-1-
phosphate (S1P), which can be irreversibly degraded by an enzyme called sphingosine-1-phosphate
lyase (S1PLyase) [214]. Therefore, suppressing endothelial S1PLyase expression by siRNA is a potential
therapeutic approach to maintain the integrity of the endothelial barrier [217]. Nanoparticles containing
siRNA targeting S1PLyase and recombinant high mobility group box-1 A peptide (HMGB1A) were
delivered to the lungs of LPS-induced ALI mouse model by intratracheal instillation. HMGB1A peptide
is an antagonist of the pro-inflammatory cytokine HMGB1 and provides additional anti-inflammatory
effect in ALI. An arginine-rich R3V6 peptide was used as a carrier. S1PLyase level was significantly
inhibited in the BALF, leading to a significantly reduction of inflammatory cytokine (TNF-α and IL-6)
and inflammatory response in the lungs of the treated animal [11].
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4.3.4. Considerations of Managing Respiratory Inflammatory Diseases by RNAi
Although several in vivo studies demonstrated promising results of using RNAi therapeutics
for the management of respiratory inflammatory diseases, there are several concerns that need to be
taken into consideration with this approach. The distribution of naked siRNA following intranasal
and intratracheal administration was investigated. It was shown that the siRNA molecules were
predominantly accumulated in the peribronchial epithelial cells within 24 h post-administration [12].
Since the inflammatory mechanism of diseases like asthma appears to be driven by the activated
Th2 lymphocytes [218], it is highly desirable for RNAi molecules to target the activated T cells
in the airways to achieve therapeutic benefit. However, specific targeting to T cells is extremely
difficult [174]. Effective T cells transfection in vitro was achieved by electroporation [219], an approach
that is not clinically feasible. Recently, a ligand-polymer conjugate siRNA delivery system,
transferrin-polyethylenimine (Tf-PEI), has been developed to target T cells in the lungs [174].
The rational of such a design was based on the increased expression of transferrin receptors on
T cells after activation. Biodistribution study showed that Tf-PEI polyplexes can selectively deliver
the fluorescently labeled siRNA to the activated T cells in a murine asthma model. However,
the therapeutic effect of the system was not evaluated. Therefore, targeting delivery of RNAi
therapeutics to specific cell types associated with the disease is a field that certainly required
further exploration.
Most of the key signaling molecules involved in the pathogenesis of respiratory inflammatory
disorders have multiple functions and participate in normal physiological activities to maintain
homeostasis. Short-term regimen (up to four days) was employed in the majority of the animal
studies. The duration of treatment may not be sufficient to observe any long-term effect. Since many
inflammatory diseases are chronic disorders, long-term therapy is often required to control the disease.
Therefore, it is crucial to evaluate the long-term effect of any RNAi therapeutics.
Inhaled corticosteroid is commonly used to control the symptoms of lung inflammatory disorders.
Steroid treatment reduces airway inflammation, partially through down-regulation of the key effectors
molecules, such as c-kit [220] and GATA3 [221]. For this reason, it is necessary to determine the effect
of concurrent medications on the expression of targeting molecules before initiating the RNAi therapy.
Given that lung inflammatory diseases are heterogeneous diseases that are categorized into different
subtypes according to the inflammatory profiles and responses to treatment, it is desirable to identify
the patients’ profile in order to maximize the benefit of RNAi therapy.
4.4. Pulmonary Fibrosis
Pulmonary fibrosis is a respiratory disorder characterized by the progressive and irreversible
destruction of lung architecture, which ultimately leads to organ malfunction, disruption of gas
exchange and even death [222]. It is initiated by lung tissue damage resulting from autoimmune
disorders or exposure to external irritants. The damage in turn triggers inflammatory reactions
for tissue repair in the attempt to restore the normal tissue architecture and functions [222].
Under pathological conditions, extracellular matrix (ECM) components, which are released by the
activated myofibroblasts during the wound healing process, are excessively produced and accumulate
at the site of tissue injury, resulting in fibrosis [223]. There are many forms of pulmonary fibrosis. All
of them are lethal diseases with high mortality rate but with very limited therapeutic options [223].
Thus pulmonary fibrosis is a lung disease with huge unmet medical need.
RNAi has been exploited to suppress the production of key molecules involved in the fibrotic
process, such as TGF-β [92,224], amphiregulin (AR) and connective transforming growth factor
(CTGF) [8,225] (Table 5). Clinical trials examining the effect of neutralized antibodies to block the
activity of TGF-β are currently ongoing [14]. Since lung epithelial cells are the key cell types in
the pathogenesis of pulmonary fibrosis, local administration of RNAi targeting TGF-β to the lungs
can ensure high local concentration of RNAi molecules to produce therapeutic effects. Intratracheal
delivery of siRNA targeting TGF-β1 could effectively inhibit pulmonary fibrosis, improved lung
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function, and prolonged survival in human TGF-β1 transgenic mice [224]. In another in vivo study,
intranasal delivery of miRNA-326 mimic, which was designed to suppresses the expression of TGF-β
and other profibrotic genes, significantly reduced TGF-β1 expression level and further alleviated the
fibrotic feature in the bleomycin-induced pulmonary fibrosis [92]. The results suggest the potential of
targeting TGF-β or its signaling pathway using RNAi technology for the management of lung fibrosis.
Table 5. Selected in vivo studies of using RNAi therapy on pulmonary fibrosis.
RNAi Administration/DeliverySystem Methods Key Observations Ref. Year
TGF-β1, CTGF,
PDGF, CCL2,
and Tissue
factor siRNA
Intratracheal/
Naked siRNA
0.05–5 mg/kg of siRNA (~1–100 µg) was
administered to mouse models of
pulmonary fibrosis (total 3 doses)
Pulmonary fibrosis was strongly
inhibited by TGF-β1 and CCL2
siRNAs, weakly inhibited by CTGF,
PDGF and tissue factor siRNAs
[224] 2012
CTGF siRNA
Intratracheal/
PEGylated
PDMAEMA
10–50 µg of siRNA was administered to
bleomycin-induced rat model of
pulmonary fibrosis
Collagen deposition and
inflammatory cytokines production
was significantly reduced
[225] 2013
miR-326 mimic
and TGF-β1
siRNA
Intranasal/Naked
siRNA
90 or 120 µg miRNA mimic, or 120 µg
siRNA was administered to
bleomycin-induced mouse model of
pulmonary fibrosis (total 4 doses)
Both treatments inhibited the
expression of TGF-β1 and
attenuated the fibrotic response
[92] 2014
AR and CTGF
siRNA
Intratracheal or
intravenous/
SAMiRNA
nanoparticles
1–5 mg/kg SAMiRNA was administered
to bleomycin or TGF-β transgenic
mouse model of pulmonary fibrosis
Collagen accumulation in the lung
of animal was effectively inhibited [8] 2016
Notes: AR, amphiregulin; CCL2, chemokine (C-C motif) ligand 2/monocyte chemoattractant
protein-1; CTGF, connective tissue growth factor; PDGF, platelet-derived growth factor; PDMAEMA,
poly(dimethylamino)ethylmethacrylate; PMAPEG: poly(methylether-methacrylate-ethyleneglycol); SAMiRNA,
self-assembled micelle interfering RNA; TGF-β, transforming growth factor β.
One complication of using TGF-β as the molecular target of RNAi is related to its physiological role
in maintaining immune and cellular homeostasis. It has a role in tumor suppression as suggested by the
finding that specific inhibition of TGF-β in mouse stromal fibroblasts results in spontaneous carcinoma
formation in the adjacent epithelium [226]. As a result, targeting the downstream effectors of TGF-β
may offer the therapeutic benefit of inhibiting the TGF-β-mediated fibrotic response while preserving
the major physiological function of the profibrotic cytokine [227]. CTGF is a key molecule that
regulates fibroblast mitosis and promotes collagen deposition in pulmonary fibrosis induced by TGF-β.
A non-viral delivery system consists of poly(dimethylamino)ethylmethacrylate (PDMAEMA) and its
copolymer with poly(methylether-methacrylate-ethyleneglycol) [PMAPEG] was used to incorporate
and form complexes with siRNA targeting CTGF. After intratracheal administration, significant
reduction of CTGF expression, collagen deposition and inflammatory cytokines (IL-6, TNF-α and
TGF-β) production were observed in bleomycin-induced lung fibrosis animal model. More importantly,
the survival rate of the animals treated with siRNA targeting CTGF was significantly increased in
comparison with the group treated with scrambled siRNA [225].
Another downstream mediator of TGF-β is amphiregulin (AR), which is an epidermal growth
factor receptor (EGFR) ligand primarily induced by TGF-β1 [228]. siRNAs targeting AR and CTGF
were delivered to the lung of pulmonary fibrosis mouse model via either intratracheal or intravenous
administration. To improve the efficiency and cell-specific delivery, a modified self-assembled micelle
interfering RNA nanoparticles (SAMiRNA) was developed. The nanoparticles contain hydrophilic
polymer and hydrophobic lipid on each ends of siRNA and can spontaneously form micelle in solution.
After administration of AR or CTGF SAMiRNAs, the expression of AR and CTGF, and collagen
accumulation in the lung of pulmonary fibrosis model were significantly reduced compared to control
SAMiRNA [8].
5. Clinical Translation and Future Perspectives
RNAi technology has been under rapid development for the last decade. The therapeutic potential
of RNAi molecules in airway diseases has been demonstrated in several clinical studies (Table 6),
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and they could be the solution to some unmet medical needs. No RNAi therapeutics has gained
approval by regulatory authority at the time this manuscript was prepared. While delivery is generally
considered as the major obstacle to RNAi therapeutics development, it is interesting to notice that
siRNAs or miRNA mimics do not need a carrier to generate therapeutic effects following pulmonary
delivery. The cellular uptake mechanism of naked RNA in the airways is not clear, but this is certainly
an attractive feature that allows simple formulation without the need of delivery vectors. Chemically
modified siRNA or miRNA is necessary to improve the stability of the RNA molecules. On the other
hand, the delivery of shRNA or miRNA encoding plasmids requires viral vectors to ensure efficient
transduction and the subsequent expression of RNAi molecules. However, the use of viral vectors
could raise safety concerns for clinical applications, especially when they are used for pulmonary
delivery. The employment of liposomal or polymer based nanoparticle delivery technology could be a
promising approach. Whether the nanoparticles or naked RNA are used, it is important to evaluate
the pharmacokinetic profile of each delivery system to ensure the RNAi therapeutics are localized at
the site of action but not quickly distributed to other organs in the body. In terms of formulation of
RNAi therapeutics, dry powder aerosol is preferred over the liquid aerosol due to higher stability and
the dry powder inhalers are easier to operate with better lung deposition [229]. This would be the
direction for RNAi formulation development.
Table 6. Summary of clinical trials of RNAi therapeutics in respiratory diseases.
RNAi Condition Delivery Status Company/Sponsor Ref/Trial ID Year
N protein
siRNA
(ALN-RSV01)
RSV infection Intranasal,naked siRNA
Phase I & II
Completed
Alnylam
Pharmaceuticals [139,140,230] 2012
N protein
siRNA
(ALN-RSV01)
RSV infection in
lung transplant
patient
Inhalation,
naked siRNA
Phase II
completed
Alnylam
Pharmaceuticals [231] 2011
Syk siRNA
(Excellair) Asthma
Inhalation,
naked siRNA
Phase I
completed
ZaBeCor
Pharmaceuticals [199,200] 2010
miR-34
(MRX34)
Solid tumor
including
NSCLC
Intravenous,
liposomes Phase I ongoing
Mirna
Therapeutics NCT01829971 2013
miR-16
(TargomiRs)
Recurrent MPM
and NSCLC
Intravenous,
nanoparticles Phase I ongoing
University of
Sydney NCT02369198 2015
Notes: MPM, malignant pleural mesothelioma; NSCLC, non-small cell lung cancer; RSV, respiratory syncytial
virus; Syk, spleen tyrosine kinase.
Among the different types of RNAi molecules for therapeutic development, siRNA has made
significant progress, with a couple of clinical studies investigate the pulmonary delivery of siRNA
to treat respiratory diseases. There are also a growing number of clinical pipelines involving
the use of siRNA and other RNAi molecules. Several key questions are raised that need to be
answered. For infectious diseases, as demonstrated in several in vivo studies, it appears that RNAi
is more effective in prophylactic regimen than in therapeutic regimen. How can we improve the
therapeutic efficacy of RNAi in combating infections to make it clinically relevant? For inflammatory
diseases, long-term therapy is expected. How can we minimize the undesirable effects when
cytokines/chemokines are being targeted? When the respiratory functions are compromised in
patients with lung disease, is pulmonary delivery a suitable route for administration? As complicated
signaling pathway is involved in the pathogenesis of different lung disorders, a thorough investigation
of the underlying pathological mechanisms of the disease is a prerequisite for identifying the target
of RNAi. Despite the challenges and obstacles, we believe that the pulmonary delivery of RNAi
molecules targeting airway diseases is promising.
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